Author | N | Study type | Intervention | Duration | Outcomes | Comments |
Masa76 | 22 | Before/after | NIV and BPAP | >4 months | Improved symptoms; ↓ hospitalisations; improved ABGs | |
Berger56 | 23 | Before/after | BPAP or CPAP | 7 years | ↓Paco2 | Therapy aimed at correcting specific sleep abnormality |
de Lucas-Ramos53 | 13 | Before/after | BPAP | 12 months | Improved, Pao2, Paco2, FVC, ΔP0.1/ΔPaco2, ΔVE/ΔPaco2 | Likely recovery of chemoreceptor sensitivity to hypercapnia following BPAP |
Perez de Llano69 | 54 | Retrospective | CPAP, BPAP and NIV | 7 years | ↑Pao2; ↓Paco2; ↓ dyspnoea, no weight change | On review, substantial number on BPAP able to be switched to CPAP |
Mokhlesi73 | 75 | Retrospective | BPAP and CPAP | Variable | Changes in Pao2 and Paco2 dependent on adherence rather than mode of therapy | |
Redolfi54 | 6 | Before/after | BPAP | 6–20 months | ↓Paco2; ↑leptin levels correlating positively with P0.1/Petco2 slope; ΔBMI by 2 kg/m2 | |
Budweiser38 | 126 | Retrospective | BPAP | 10 years | ↓Nocturnal Paco2 by >23% and Hb compared with baseline associated with improved prognosis | |
Heinemann75 | 35 | Before/after | BPAP | 12 and 24 months | Normalisation of Paco2 and reduced base excess; ↓polycythemia; ↑ in VC and TLC; ↓RV/TLC |
ABG, arterial blood gas; BMI, body mass index; BPAP, bilevel positive airway pressure; CPAP, continuous positive airway pressure; FVC, forced vital capacity; NIV, non-invasive ventilation; OHS, obesity hypoventilation syndrome; P0.1, occlusion pressure; Paco2, Pao2, arterial carbon dioxide and oxygen tensions; RV, residual volume; TLC, total lung capacity; VC, vital capacity; VE, minute ventilation.